Funded Biotechnology Startups
Among the 29 most recent biotechnology/pharmaceuticals funding entries shown (dated 2025-09-11 through 2026-06-24), one disclosed round stands out: Ollin B…
Among the 29 most recent biotechnology/pharmaceuticals funding entries shown (dated 2025-09-11 through 2026-06-24), one disclosed round stands out: Ollin Biosciences raised $330M on 2026-06-24, which dwarfs the next-largest disclosed amounts (e.g., Adcytherix at $122M on 2025-10-16 and AusperBio at $63M on 2025-09-28). Disclosed amounts cluster heavily in the $5M–$56M range, while several entries are “undisclosed” (including Healsun Biopharm on 2025-11-21, Miramoon Pharma on 2025-11-18, and others).
Geographically, China appears repeatedly (notably Hangzhou: Healsun Biopharm at 2025-11-21 is undisclosed; Kind Pharmaceutical at 2025-11-13 is $56M; Vybio at 2025-11-10 is $14M; plus several other Chinese cities), suggesting a concentrated cross-border pattern rather than a single-city hub. Stage reporting is mixed: disclosed rounds span Seed through Series B, and there are multiple “Venture - Series Unknown” records (Dayra Therapeutics on 2025-11-26 for $20M; Oligon on 2025-09-22 for $14M; Enlaza Therapeutics on 2025-09-13 for $15M), alongside several “undisclosed” amounts.
Most recent rounds
29 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how far above the rest is it?
Ollin Biosciences’ $330M on 2026-06-24 is the only disclosed round far above the pack; the next-largest disclosed amounts are $122M (Adcytherix, 2025-10-16) and $63M (AusperBio, 2025-09-28). Everything else with disclosed amounts sits below $56M (e.g., Kind Pharmaceutical at $56M on 2025-11-13).
Are there noticeable city or country concentrations across these 29 entries?
China is repeatedly represented across different cities, with multiple Hangzhou entries such as Kind Pharmaceutical ($56M on 2025-11-13) and Vybio ($14M on 2025-11-10), alongside other Chinese locations like Shanghai (Brise Pharma at $28M on 2025-11-10) and Guangdong (RabPharma, amount undisclosed, 2025-09-12). The pattern looks multi-city rather than a single local cluster.
Which companies are most recent in the dataset window?
The most recent date shown is 2026-06-24, held by Ollin Biosciences ($330M). The next cluster of recent rounds is largely concentrated in late 2025, including Dayra Therapeutics (2025-11-26, $20M) and Healsun Biopharm (2025-11-21, undisclosed).
Do undisclosed amounts or “Series Unknown” labels limit comparability?
Several entries list “undisclosed” amounts (e.g., Healsun Biopharm on 2025-11-21 and Miramoon Pharma on 2025-11-18), which means comparisons of “largest” and “typical” size depend on the subset with disclosed figures. Separately, there are “Venture - Series Unknown” rounds with disclosed amounts: Dayra Therapeutics ($20M on 2025-11-26), Oligon ($14M on 2025-09-22), and Enlaza Therapeutics ($15M on 2025-09-13).
Is there a stage mix signal when comparing early vs later rounds in this slice?
Even within this 29-row window, later disclosed rounds (e.g., Series B) include OncoC4 at $50M (2025-10-05) and AusperBio at $63M (2025-09-28), while early-stage disclosed rounds also appear (e.g., Seed: Chirality Biosciences at $3M on 2025-11-02; HiDiamond Biotechnology at $14M on 2025-09-16). Seed and Series B both show up with disclosed amounts rather than one stage dominating the disclosed-size range.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.